Stem Cell Clinic

Doctors claim cerebral palsy 'cure'

Research into stem cell treatments has shown promising progress Photograph: Getty Images

Medics in Germany said they have successfully treated a child with cerebral palsy for the first time.

Just weeks after being given an intravenous stem cell treatment from umbilical cord blood, the symptoms of a boy who had been left in a vegetative state after a heart attack improved considerably and within months he could talk and move.

The doctors who carried out the treatment said the results of the treatment dispel "long-held doubts" surrounding the effectiveness of stem cell therapy.

After going into cardiac arrest in November 2008, the two-year-old boy, known only as LB, was left paralysed with severe brain damage and in a vegetative state. Doctors warned his parents that his chances of survival were minimal.

Until now, there has been no treatment for the cause of what is known as infantile cerebral palsy.

Dr Arne Jensen of the Campus Clinic Gynaecology in Bochum, who carried out the new treatment, said: "In their desperate situation, the parents searched the literature for alternative therapies. They contacted us and asked about the possibilities of using their son's cord blood, frozen at his birth."

Nine weeks after the brain damage, on January 27, 2009, the doctors administered the prepared blood intravenously.

They studied the progress of recovery at two, five, 12, 24, 30 and 40 months after his brain injury.

Usually, the chances of survival after such severe brain damage and more than 25 minutes of resuscitation are just 6%.

Read this article:
Doctors claim cerebral palsy 'cure'

Foolhardy expectations from stem cell products

Medical Files By Rafael Castillo Philippine Daily Inquirer

I have received a couple of queries regarding capsules or drink solutions which are supposed to boost the number of stem cells in the body and these could assist in cellular renewal or rejuvenation. I understand these are being marketed locally by direct sellers who are part of multilevel networking companies.

These stem-cell-enhancing preparations come from blue-green algae sources, which as far back as I can remember, have been promoted to be a panacea for all sorts of illnesses. Apparently the claim that it can boost stem cell production or its release from the bone marrow puts a scientific basis to it, which is attuned with the times since stem cell treatment is now the exciting buzz word.

I last reviewed the scientific literature on stem cell treatment earlier this year when I was requested to give a lecture partly discussing the effects of adult stem cells on the cardiovascular system. I remember coming across some articles on the potential role of blue-green algae in enhancing stem cell production but most of these studies were done either on mice and other experimental animals or in tissue cultures in the laboratory. Theres still a long way between any positive results noted in these experiments to actual clinical benefits that can be extrapolated in humans.

Time and again we hear of and read so many clinical trials showing a negative effect of a drug in humans when all its preclinical trials in experimental animals and small trials in few healthy human volunteers showed beneficial results with no evidence of harm or toxicity.

First do no harm

In the practice of medicine, a cardinal rule is First do no harm. There is still an unresolved issue about the potential toxicity of some blue-green algae preparations. Some products have been shown to contain a significant amount of toxins which can potentially cause liver failure. I cant remember the number of cases of liver toxicity reported for which blue-green algae has been implicated.

If theres smoke, there might be fire. Unless the smoke really clears and the potential harm and toxicity by blue-green algae are ruled out, it would probably be not good advice to take it.

I have nothing against natural dietary supplements so long as theres no reason to worry about any potential harm, and the reported benefits have scientific basis. When patients show me all sorts of supplements and ask if they could take them, I usually tell them to go ahead unless theres reasonable doubt about the products safety. In fact, I take and prescribe a few tried-and-tested supplements myself.

It cant be overemphasized and I think its worth reiterating that there are still a lot of unanswered questions in stem cell science, and exploiting it for commercial reasons is doing the consumers a lot of disservice. Telling them only half of the story, insofar as the effectiveness and safety of the product is concerned, is also being quite deceptive.

Read more from the original source:
Foolhardy expectations from stem cell products

BioTime Announces Results of Vote at Special Meeting of Shareholders

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX) today announced that at a Special Meeting held on May 21, 2013, its shareholders approved the proposals related to the planned acquisition of stem cell related assets from Geron Corporation by BioTimes subsidiary Asterias Biotherapeutics, Inc. (Asterias). Each of the proposals received at least 32,459,164 votes in favor from the 34,450,307 shares that were represented and voted, in person or by proxy, at the meeting. Additional information concerning the proposals approved at the Special Meeting and the vote totals can be found in a Form 8-K that BioTime has filed with the Securities and Exchange Commission.

Approvals of the Share Issuance Proposal and the Articles Amendment Proposal were necessary for the acquisition of stem cell related assets from Geron Corporation under the Asset Contribution Agreement, as the approval of those proposals satisfies one of the conditions required to be met in order to complete the asset contribution transaction.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap Sciences also markets BioTime research products and PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com

Here is the original post:
BioTime Announces Results of Vote at Special Meeting of Shareholders

Stem cell therapies sans FDA OK illegal

The Food and Drug Administration (FDA) has warned the public and tourists against getting stem cell therapies in the country without its approval.

FDA acting Director General Kenneth Hartigan-Go issued the advisory after it received complaints from the public and health professionals that stem cell therapies are conducted in non-health facilities, such as hotel rooms. He cautioned people from receiving stem cell preparations and therapies that were not approved by the FDA. Go said the following stem cell preparations require FDA approval: genetically altered human adult and umbilical cord stem cells; adipose or fat cells derived human stem cell; human cells, tissues, and cellular and tissue-based products that are subjected to genetic manipulation; and live animal embryonic, fetal, or adult stem cells in parental form for human administration. The FDA said it does not allow the creation, importation, promotion, marketing and use of human embryos, human embryonic stem cells and their derivatives, aborted human fetal stem cells and their derivatives for human treatment and research, as well as plant parts labeled as stem cells. (Jonathan Hicap)

Previous

Next

View original post here:
Stem cell therapies sans FDA OK illegal

Risks of cerebral palsy stem cell treatment

An expert panel of scientists and clinicians is warning people against going overseas for costly and unproven stem cell treatment for cerebral palsy.

A forum held in Sydney last night heard from leading researchers in the field and a parent who sought treatment in the United States for his young son.

The Cerebral Palsy Alliance estimates as many as 500 Australians have sought stem cell therapies overseas.

But the alliance last night urged families to hold out for the possibility that Australia will undertake its own clinical trials of the treatment as early as this year.

"We're very worried about families travelling overseas for treatment," Associate Professor Iona Novak, from the alliance, said.

"A lot of these stem cell tourism companies don't even describe what type of cells they're giving, so first we don't even know if they're human cells... so, of course, it is a very risky procedure.

"There has been a couple of cases internationally of children actually dying from these treatments."

The alliance estimates a child in Australia is born with cerebral palsy every 15 hours, making it the most common disability in childhood.

The condition is caused by damage to the child's brain during pregnancy, birth or soon after.

It often leads to seizures, blindness, hearing loss and slower developmental growth.

More:
Risks of cerebral palsy stem cell treatment

Italy approves law on controversial stem cell therapy

ROME: Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill children.

The law gives the go-ahead for therapy being carried out by the Stamina Foundation on dozens of patients to continue, and allows for an 18-month period of clinical trials for the procedure, which had previously been blocked by Italian authorities.

The bill was amended from an earlier version and states the therapy must be carried out under regulatory oversight and using cells made according to the Good Manufacturing Practice (GMP) which the Stamina Foundation has not adhered to.

The Stamina Foundation says its treatment is based on mesenchymal stem cells and could treat diseases like spinal cord injury and motor neurone disease.

But leading scientists have warned that there is no evidence to suggest the treatment could work and no way to know that it will not cause harm.

Patients lobbied for the therapy to be given the go-ahead, receiving support from various celebrities including actress Gina Lollobrigida.

At one demonstration, protesters wore T-shirts with the slogan: "Yes to Stamina, Yes to Life".

The association Stem Cell Research Italy has branded the new law as "unacceptable" saying the therapy was not backed up by clinical data published in peer-reviewed academic journals.

US journal Nature said it was a "rogue" therapy.

Read more from the original source:
Italy approves law on controversial stem cell therapy

Italy approves controversial stem cell therapy

Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill children.

The law gives the go-ahead for therapy being carried out by the Stamina Foundation on dozens of patients to continue, and allows for an 18-month period of clinical trials for the procedure, which had previously been blocked by Italian authorities.

The bill was amended from an earlier version and states the therapy must be carried out under regulatory oversight and using cells made according to the Good Manufacturing Practice (GMP) which the Stamina Foundation has not adhered to.

The Stamina Foundation says its treatment is based on mesenchymal stem cells and could treat diseases like spinal cord injury and motor neurone disease.

But leading scientists have warned that there is no evidence to suggest the treatment could work and no way to know that it will not cause harm.

Patients lobbied for the therapy to be given the go-ahead, receiving support from various celebrities including actress Gina Lollobrigida.

At one demonstration, protesters wore T-shirts with the slogan: "Yes to Stamina, Yes to Life".

The association Stem Cell Research Italy has branded the new law as "unacceptable" saying the therapy was not backed up by clinical data published in peer-reviewed academic journals.

US journal Nature said it was a "rogue" therapy.

Read the original post:
Italy approves controversial stem cell therapy

Scientists warn against risking cerebral palsy stem cell treatment overseas

An expert panel of scientists and clinicians is warning people against going overseas for costly and unproven stem cell treatment for cerebral palsy.

A forum held in Sydney last night heard from leading researchers in the field and a parent who sought treatment in the United States for his young son.

The Cerebral Palsy Alliance estimates as many as 500 Australians have sought stem cell therapies overseas.

But the alliance last night urged families to hold out for the possibility that Australia will undertake its own clinical trials of the treatment as early as this year.

"We're very worried about families travelling overseas for treatment," Associate Professor Iona Novak, from the alliance, said.

"A lot of these stem cell tourism companies don't even describe what type of cells they're giving, so first we don't even know if they're human cells... so, of course, it is a very risky procedure.

"There has been a couple of cases internationally of children actually dying from these treatments."

The alliance estimates a child in Australia is born with cerebral palsy every 15 hours, making it the most common disability in childhood.

The condition is caused by damage to the child's brain during pregnancy, birth or soon after.

It often leads to seizures, blindness, hearing loss and slower developmental growth.

More here:
Scientists warn against risking cerebral palsy stem cell treatment overseas

BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference

JUPITER, Fla., May 21, 2013 /PRNewswire/ --BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that Mark Weinreb, its President and CEO, will be presenting at the Marcum MicroCap Conference.

The conference will be held on Thursday, May 30, 2013 at the Grand Hyatt Hotel, located at 109 E 42nd Street in New York City. Mr. Weinreb's presentation will take place at 2:30 ET in room six. To listen to the webcast, please visit http://wsw.com/webcast/marcum/brtx.

The event will host nearly 100 publicly traded companies with capitalizations under $500 million. It is anticipated that the conference will be attended by more than 1,000 persons, including senior personnel from the presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace. The conference will also feature panels on subjects highly relevant to small-cap corporate finance.

For full event details and registration information, please go to: http://www.marcumllp.com/microcap

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ("BRT"), http://www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls brand at http://www.stempearls.com.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contact:Jeff Ramson ProActive Capital (646) 863-6341 jramson@proactivecapital.com

Excerpt from:
BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference